's () CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London.
The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business.
Paterson says the focus is now firmly on the Adapt division - advancing its Transcatheter Aortic Valve Replacement (TAVR) program and other potential products.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE